Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eltrekibart
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Anti-inflammatory mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Eltrekibart is a humanized IgG4 kappa monoclonal antibody developed by Eli Lilly that neutralizes all seven ELR+ CXC chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8), thereby inhibiting signaling through the chemokine receptors CXCR1 and CXCR2. By blocking these chemokines—which are involved in inflammation and immune responses—eltrekibart aims to reduce inflammatory activity. It is being investigated primarily for the treatment of moderate to severe hidradenitis suppurativa and has also entered phase II clinical trials for ulcerative colitis. The drug is administered as an intravenous or subcutaneous injection[1][3][5][7].
- Other names
- eltrekibart
02
Targets
CXCR1 (C-X-C chemokine receptor 1)CXCR2 (C-X-C Motif Chemokine Receptor 2)
Beyond the preview
Go deeper on eltrekibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eltrekibart.